Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1007/s00393-016-0256-2
Published Online: 2017-01-13
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gissel, C.
Götz, G.
Repp, H.
License valid from 2017-01-13